TissueGen to Highlight ELUTE® Fiber for Advanced Drug Delivery, Nerve Regeneration and Tissue Engineering at MD&M East

01 Jun TissueGen to Highlight ELUTE® Fiber for Advanced Drug Delivery, Nerve Regeneration and Tissue Engineering at MD&M East

Explore How ELUTE® Fiber is Ideal for Orthopedic Applications Requiring Targeted Cell Migration and Tissue Growth

WHO: TissueGen® Inc., developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering.

WHAT: TissueGen will exhibit patented ELUTE fiber in booth 2029 at MD&M East.  ELUTE fiber enables controlled sustained delivery of a broad range of sensitive biologics and pharmaceuticals for topical and implantable medical applications. TissueGen’s patented manufacturing processes overcome the challenges of heat and shear stress typically associated with melt extrusion and provides the potential benefit of localized, non-systemic drug delivery and structural support not possible from other drug delivery formats such as microspheres and nanoparticles. Because TissueGen’s extrusion processes occur at or below body temperature, ELUTE fiber enables delivery of the broadest range of sensitive biologics and pharmaceuticals possible from biodegradable fiber-based topical and implantable devices for advanced drug delivery, nerve regeneration, and tissue engineering. For more information, download TissueGen’s free white paper //www.tissuegen.com/technology/white-papers/

One application where biodegradable biologic-loaded fiber holds tremendous promise is orthopedics where ELUTE fiber can serve as a critical component in medical textiles for repair of soft tissue.  Because the human tissue targeted in orthopedic procedures such as repair of tendons, ligaments and muscle tissue are inherently fibrous in nature, fiber-based medical devices are highly compatible with surrounding tissue structure and organization. For example, ELUTE fiber-based medical textiles serving as active scaffolding may deliver growth factors that selectively direct cell migration and tissue growth.

Christopher Knowles, President and CEO, will be available at MD&M East to discuss the ELUTE fiber and how this technology may revolutionize a wide range of medical applications.

WHERE:
MD&M East
Booth 2029
Javits Convention Center
New York, NY

WHEN: MD&M East will take place from June 13-15, 2017.

To schedule a briefing, please contact Jordan Bouclin at Jordan.bouclin@svmpr.com or (401)490-9700.

 

About TissueGen

TissueGen® Inc. is the developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering. TissueGen manufactures biodegradable polymer-based fibers with the broadest drug delivery capabilities available today. ELUTE fiber can directly replace standard fibers used in medical devices currently on the market and may provide significantly improved clinical outcomes by delivering sensitive therapeutic agents directly at the implant or topical application site in controlled, sustained release profiles. ELUTE fiber may enable medical device developers to guide the body’s healing and regenerative processes.

For more information, please visit www.tissuegen.com.

# # #

For more information contact:

Jordan Bouclin
SVM Public Relations
401-490-9700
jordan.bouclin@svmpr.com

 

 

 

 

 

No Comments

Sorry, the comment form is closed at this time.